Literature DB >> 2494957

Antibody to phosphatidylethanolamine in a patient with lupus anticoagulant and thrombosis.

H L Staub1, E N Harris, M A Khamashta, G Savidge, W H Chahade, G R Hughes.   

Abstract

Most patients with lupus anticoagulant (LA) activity have coincident antibodies to a group of negatively charged phospholipids, and its is suggested that LA and anticardiolipin tests detect antibodies with overlapping specificities. Some discordance between the two assays has been described, however. One patient presenting with severe thrombotic disease (recurrent deep vein thrombosis, pulmonary embolism, inferior venocaval obstruction, myocardial infarction, and digital gangrene) showed strong LA activity in February 1987. An enzyme linked immunosorbent assay (ELISA) showed no binding to the negatively charged phospholipids cardiolipin, phosphatidylserine, and phosphatidic acid, but binding to zwitterionic phosphatidylethanolamine (PE) was demonstrated. Inhibition studies and affinity purification confirmed this finding. Interestingly, the serum did not bind to the kaolin cephalin clotting time reagent when used as antigen in an ELISA. The pathogenic significance of anti-PE antibodies and their relation to LA remains to be clarified. Further studies of the occurrence of anti-PE antibodies in patients with LA activity who have negative anticardiolipin tests are suggested.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2494957      PMCID: PMC1003707          DOI: 10.1136/ard.48.2.166

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  13 in total

1.  The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies.

Authors:  R R PROCTOR; S I RAPAPORT
Journal:  Am J Clin Pathol       Date:  1961-09       Impact factor: 2.493

2.  Detection and quantitative evaluation of lupus circulating anticoagulant activity.

Authors:  E Rosner; R Pauzner; A Lusky; M Modan; A Many
Journal:  Thromb Haemost       Date:  1987-04-07       Impact factor: 5.249

Review 3.  Anti-phospholipid antibodies.

Authors:  E N Harris; A E Gharavi; G R Hughes
Journal:  Clin Rheum Dis       Date:  1985-12

4.  Thrombosis, abortion, cerebral disease, and the lupus anticoagulant.

Authors:  G R Hughes
Journal:  Br Med J (Clin Res Ed)       Date:  1983-10-15

Review 5.  Lupus anticoagulants.

Authors:  S S Shapiro; P Thiagarajan
Journal:  Prog Hemost Thromb       Date:  1982

6.  The anticardiolipin syndrome.

Authors:  G R Hughes
Journal:  Clin Exp Rheumatol       Date:  1985 Oct-Dec       Impact factor: 4.473

7.  Immunological specificity and mechanism of action of IgG lupus anticoagulants.

Authors:  V Pengo; P Thiagarajan; S S Shapiro; M J Heine
Journal:  Blood       Date:  1987-07       Impact factor: 22.113

8.  Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test.

Authors:  E N Harris; J K Chan; R A Asherson; V R Aber; A E Gharavi; G R Hughes
Journal:  Arch Intern Med       Date:  1986-11

9.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

10.  Deficiency of protein C in congenital thrombotic disease.

Authors:  J H Griffin; B Evatt; T S Zimmerman; A J Kleiss; C Wideman
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  11 in total

Review 1.  Antiphospholipid syndrome: linking many specialties.

Authors:  G R Hughes; R A Asherson; M A Khamashta
Journal:  Ann Rheum Dis       Date:  1989-05       Impact factor: 19.103

2.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

Review 3.  Antigenic specificities of "antiphospholipid" autoantibodies.

Authors:  R A Roubey
Journal:  Springer Semin Immunopathol       Date:  1994

Review 4.  The antiphospholipid antibody dilemma.

Authors:  R H Derksen; P Hasselaar; J D Oosting; P G De Groot
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

5.  Early endosome as a pathogenic target for antiphosphatidylethanolamine antibodies.

Authors:  Songwang Hou; Heike Fölsch; Ke Ke; Joan Cook Mills; Rosalind Ramsey-Goldman; Ming Zhao
Journal:  Proc Natl Acad Sci U S A       Date:  2017-12-11       Impact factor: 11.205

6.  Lysophosphatidylethanolamine is the antigen to which apparent antibody to phosphatidylethanolamine binds.

Authors:  T Qamar; A E Gharavi; R A Levy; M D Lockshin
Journal:  J Clin Immunol       Date:  1990-07       Impact factor: 8.317

Review 7.  The 'antiphospholipid syndrome' and the 'lupus anticoagulant'.

Authors:  J S Cameron; G Frampton
Journal:  Pediatr Nephrol       Date:  1990-11       Impact factor: 3.714

8.  The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.

Authors:  Songwang Hou; Paul E Harper; Nathalie Bardin; Ming Zhao
Journal:  J Immunol Methods       Date:  2016-10-23       Impact factor: 2.303

9.  Influence of Phosphatidylethanolamine Concentration and Composition on the Detection of Antiphosphatidylethanolamine Antibodies by ELISA.

Authors:  Ke Ke; Zachariah I Strango; Paul E Harper; Ming Zhao
Journal:  J Clin Lab Anal       Date:  2016-04-07       Impact factor: 2.352

10.  On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies.

Authors:  M D Smirnov; D T Triplett; P C Comp; N L Esmon; C T Esmon
Journal:  J Clin Invest       Date:  1995-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.